Wolleschak, D., Mack, T. S., Perner, F., Frey, S., Schnöder, T. M., Wagner, M.-C., Höding, C., Pils, M. C., Parkner, A., Kliche, S., Schraven, B., Hebel, K., Brunner-Weinzierl, M., Ranjan, S., Isermann, B., Lipka, D. B., Fischer, T. and Heidel, F. H. (2014) “Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function”, Haematologica. Pavia, Italy, 99(6), pp. e90-e93. doi: 10.3324/haematol.2014.104331.